Suppr超能文献

卡麦角林与复方口服避孕药对高泌乳素血症年轻女性的心脏代谢影响:一项初步研究

Cardiometabolic Effects of Cabergoline and Combined Oral Contraceptive Pills in Young Women with Hyperprolactinemia: A Pilot Study.

作者信息

Krysiak Robert, Kowalcze Karolina, Okopień Bogusław

机构信息

Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.

Department of Pediatrics in Bytom, School of Health Sciences in Katowice, Medical University of Silesia, Stefana Batorego 15, 41-902 Bytom, Poland.

出版信息

J Clin Med. 2023 Apr 29;12(9):3208. doi: 10.3390/jcm12093208.

Abstract

Although dopaminergic agents are the drugs of choice in treatment of prolactin excess, women who cannot be treated with these agents are recommended to receive estrogen preparations. The aim of this study was to compare cardiometabolic effects of both treatment options. The study population included three groups of young women. Subjects with mild-to-moderate hyperprolactinemia received either low-dose cabergoline or oral combined contraceptives (ethinyl estradiol plus desogestrel), while normoprolactinemic women were drug-naive. Plasma prolactin, glucose homeostasis markers, lipids, circulating levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine, and the urinary albumin-to-creatinine ratio (UACR) were assessed at entry and six months later. Hyperprolactinemic women differed from normoprolactinemic ones in glucose homeostasis markers, high-density lipoprotein (HDL)-cholesterol, triglycerides, uric acid, hsCRP, fibrinogen, homocysteine and UACR. Cabergoline decreased total and monomeric prolactin levels, which was accompanied by normalization of glucose, insulin sensitivity, glycated hemoglobin, HDL-cholesterol, triglycerides, uric acid, hsCRP, fibrinogen, homocysteine and UACR. Despite a neutral effect on prolactin levels, combined contraceptives worsened insulin sensitivity and increased triglycerides, hsCRP, fibrinogen and UACR. At follow-up, cabergoline-treated women were characterized by a better cardiometabolic profile than women receiving ethinyl estradiol plus desogestrel. Our findings suggest that only cabergoline reduces cardiometabolic risk in young women with hyperprolactinemia.

摘要

尽管多巴胺能药物是治疗高催乳素血症的首选药物,但对于无法使用这些药物治疗的女性,建议使用雌激素制剂。本研究的目的是比较这两种治疗方案对心脏代谢的影响。研究人群包括三组年轻女性。患有轻度至中度高催乳素血症的受试者接受低剂量卡麦角林或口服复方避孕药(炔雌醇加去氧孕烯),而催乳素水平正常的女性未使用过药物。在入组时和六个月后评估血浆催乳素、葡萄糖稳态标志物、脂质、尿酸循环水平、高敏C反应蛋白(hsCRP)、纤维蛋白原和同型半胱氨酸,以及尿白蛋白与肌酐比值(UACR)。高催乳素血症女性在葡萄糖稳态标志物、高密度脂蛋白(HDL)胆固醇、甘油三酯、尿酸、hsCRP、纤维蛋白原、同型半胱氨酸和UACR方面与催乳素水平正常的女性不同。卡麦角林降低了总催乳素和单体催乳素水平,同时血糖、胰岛素敏感性、糖化血红蛋白、HDL胆固醇、甘油三酯、尿酸、hsCRP、纤维蛋白原、同型半胱氨酸和UACR也恢复正常。尽管复方避孕药对催乳素水平无影响,但却恶化了胰岛素敏感性,增加了甘油三酯、hsCRP、纤维蛋白原和UACR。在随访中,接受卡麦角林治疗的女性的心脏代谢状况优于接受炔雌醇加去氧孕烯治疗的女性。我们的研究结果表明,只有卡麦角林能降低年轻高催乳素血症女性的心脏代谢风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94a6/10179073/0687cde8950f/jcm-12-03208-g001.jpg

相似文献

2
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
J Clin Pharmacol. 2023 Aug;63(8):886-894. doi: 10.1002/jcph.2245. Epub 2023 May 8.
4
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
J Clin Pharmacol. 2023 Mar;63(3):345-351. doi: 10.1002/jcph.2163. Epub 2022 Nov 2.
5
Cardiometabolic profile of young women with hypoprolactinemia.
Endocrine. 2022 Oct;78(1):135-141. doi: 10.1007/s12020-022-03145-1. Epub 2022 Jul 29.
6
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Cardiology. 2022;147(5-6):497-506. doi: 10.1159/000527333. Epub 2022 Oct 4.
7
Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Exp Clin Endocrinol Diabetes. 2021 Jan;129(1):7-13. doi: 10.1055/a-0902-4439. Epub 2019 Jun 11.
8
Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Am J Cardiol. 2019 Oct 15;124(8):1207-1212. doi: 10.1016/j.amjcard.2019.07.017. Epub 2019 Jul 23.
9
The effect of oral contraception on cardiometabolic risk factors in women with elevated androgen levels.
Pharmacol Rep. 2017 Feb;69(1):45-49. doi: 10.1016/j.pharep.2016.09.013. Epub 2016 Sep 15.
10
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
J Clin Pharmacol. 2019 Jan;59(1):83-89. doi: 10.1002/jcph.1301. Epub 2018 Aug 21.

引用本文的文献

1
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.
Endocr Rev. 2025 Jan 10;46(1):80-148. doi: 10.1210/endrev/bnae026.
2
The Course of Minipuberty in Daughters of Women with Low Gestational Vitamin D Status.
Nutrients. 2024 Jul 21;16(14):2362. doi: 10.3390/nu16142362.

本文引用的文献

1
Hyperprolactinemia and insulin resistance.
Endokrynol Pol. 2022;73(6):959-967. doi: 10.5603/EP.a2022.0075.
3
Hyperprolactinaemia.
J Clin Med. 2019 Dec 13;8(12):2203. doi: 10.3390/jcm8122203.
4
Drug-Induced Hypertension.
Endocrinol Metab Clin North Am. 2019 Dec;48(4):859-873. doi: 10.1016/j.ecl.2019.08.013. Epub 2019 Sep 17.
5
Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.
Front Endocrinol (Lausanne). 2019 May 22;10:327. doi: 10.3389/fendo.2019.00327. eCollection 2019.
6
Dopamine Agonists: From the 1970s to Today.
Neuroendocrinology. 2019;109(1):34-41. doi: 10.1159/000499470. Epub 2019 Mar 11.
7
The effects of hyperprolactinemia and its control on metabolic diseases.
Expert Rev Endocrinol Metab. 2018 Mar;13(2):99-106. doi: 10.1080/17446651.2018.1434412. Epub 2018 Feb 7.
8
Prolactin and Autoimmunity.
Front Immunol. 2018 Feb 12;9:73. doi: 10.3389/fimmu.2018.00073. eCollection 2018.
9
Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein.
Ann Biol Clin (Paris). 2017 Apr 1;75(2):225-229. doi: 10.1684/abc.2017.1232.
10
Markers of Early Vascular Ageing.
Curr Pharm Des. 2017;23(22):3200-3204. doi: 10.2174/1381612823666170328142433.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验